Payment overview · 2025
General Payments
$565.25
31 reported records · 16 companies
Healthcare provider profile · identity verified
John E Oxler, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHAWNEE MISSION, KS · NPI 1083619555
Verified facts
What the public records show
CMS Open Payments records show John E Oxler, MD received $565.25 in general payments during 2025 across 31 reported records.
ABBVIE INC. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $144.08 | 25.5% | 9 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $71.18 | 12.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.86 | 9.7% | 3 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $35.90 | 6.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $35.32 | 6.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.57 | 5.6% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.53 | 5.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.17 | 5.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.19 | 4.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.57 | 3.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.52 | 3.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.19 | 3.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $15.69 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.39 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.12 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.97 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $565.25 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $95.46 | 7 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $71.18 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.62 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.90 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.90 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $35.90 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $34.53 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.57 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.57 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.53 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.17 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 101 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 602 | 159 |
| Losartan Potassium | Losartan Potassium | 448 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 417 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 94 |
| Metformin Hcl | Metformin Hcl | 313 | 73 |
| Simvastatin | Simvastatin | 273 | 70 |
| Gabapentin | Gabapentin | 268 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 267 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 71 |
| Lisinopril | Lisinopril | 233 | 60 |
| Meloxicam | Meloxicam | 230 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 44 |
| Furosemide | Furosemide | 179 | 44 |
| Alprazolam | Alprazolam | 174 | 40 |
| Allopurinol | Allopurinol | 141 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 30 |
| Omeprazole | Omeprazole | 141 | 39 |
| Potassium Chloride | Potassium Chloride | 140 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 108 | 59 |
| Trazodone Hcl | Trazodone Hcl | 103 | 19 |
| Eliquis | Apixaban | 101 | 21 |
| Atenolol | Atenolol | 94 | 24 |
| Memantine Hcl | Memantine Hcl | 92 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 91 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 17 |
| Temazepam | Temazepam | 81 | 13 |
| Cefdinir | Cefdinir | 79 | 62 |
| Clonazepam | Clonazepam | 75 | suppressed |
| Methylprednisolone | Methylprednisolone | 74 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 24 |
| Sertraline Hcl | Sertraline Hcl | 70 | 15 |
| Azithromycin | Azithromycin | 65 | 49 |
| Carvedilol | Carvedilol | 64 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 47 |
| Finasteride | Finasteride | 64 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 14 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 16 |
| Tramadol Hcl | Tramadol Hcl | 53 | 17 |
| Celecoxib | Celecoxib | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 18 |
| Lovastatin | Lovastatin | 47 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 16 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 18 |
| Diazepam | Diazepam | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $565.25 · 31 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, BEYFORTUS, CeQur Simplicity, ELIQUIS, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, LEQVIO, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAQEL, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error